AGFA-GEVAERT NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.238 EUR | +0.65% |
|
+6.36% | -15.78% |
| Mar. 13 | Transcript : Agfa-Gevaert NV, 2023 Earnings Call, Mar 13, 2024 | |
| Mar. 13 | Agfa-Gevaert NV Reports Impairment Losses on Intangibles and Pp&E for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.18 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -15.78% | 206M | B+ | ||
| +7.84% | 218B | B | ||
| +7.35% | 184B | B- | ||
| +13.04% | 135B | B- | ||
| +26.03% | 107B | A- | ||
| -1.33% | 62.38B | A- | ||
| +11.80% | 51.37B | B+ | ||
| +4.81% | 50.9B | B+ | ||
| +0.30% | 40.87B | A | ||
| +2.78% | 36.28B | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- AGFB Stock
- Ratings Agfa-Gevaert NV
